Imidazole propionate: a new direction for atherosclerosis prevention and treatment

References

[1] Hoogeveen RC.Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation.Clin Chem2021;67:143-53 PMCID:PMC7793228

[2] Mensah GA,Prabhu SD,Welty FK.Inflammation and cardiovascular disease: 2025 ACC scientific statement: a report of the American College of Cardiology.J Am Coll Cardiol2026;87:1381-404

[3] Mastrangelo A,Mañanes D.Imidazole propionate is a driver and therapeutic target in atherosclerosis.Nature2025;645:254-61 PMCID:PMC12408353

[4] Molinaro A,Bel Lassen P.Microbially produced imidazole propionate is associated with heart failure and mortality.JACC Heart Fail2023;11:810-21

[5] Fan J,Watanabe T.Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine.Pharmacol Ther2015;146:104-19 PMCID:PMC4304984

[6] Jia L,Zhao Y.Tripeptide DT-109 (Gly-Gly-Leu) attenuates atherosclerosis and vascular calcification in nonhuman primates.Sig Transduct Target Ther2025;10:122 PMCID:PMC11977015

[7] Bousquet P,García-Sevilla JA.Imidazoline receptor system: the past, the present, and the future.Pharmacol Rev2020;72:50-79

[8] Wang Z,Bennett BJ.Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.Nature2011;472:57-63 PMCID:PMC3086762